FG-2101

FG-2101 is a non-hydroxamate small molecule antibiotic candidate developed by Blacksmith Medicines. It is designed to selectively inhibit UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC), a zinc-dependent metalloenzyme found only in Gram-negative bacteria. By targeting LpxC, FG-2101 disrupts the biosynthesis of lipid A, an essential component of the outer membrane in Gram-negative bacteria, making it effective against drug-resistant strains. The compound features a 3-hydroxy-2-pyrimidinone metal-binding motif discovered through fragment-based and structure-based drug design approaches. FG-2101 is being developed for both intravenous and oral administration to treat serious bacterial infections, including urinary tract infections caused by Gram-negative pathogens.

Other names

LpxC inhibitorBlacksmith LpxC program